219 related articles for article (PubMed ID: 21437987)
41. Globus pallidus stimulation in advanced Parkinson's disease.
Rodrigues JP; Walters SE; Watson P; Stell R; Mastaglia FL
J Clin Neurosci; 2007 Mar; 14(3):208-15. PubMed ID: 17150360
[TBL] [Abstract][Full Text] [Related]
42. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
43. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
44. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
45. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
46. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
47. Rasagiline treatment effects on parkinsonian tremor.
Lew MF
Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
[TBL] [Abstract][Full Text] [Related]
48. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
[TBL] [Abstract][Full Text] [Related]
49. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Hoy SM; Keating GM
Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
[TBL] [Abstract][Full Text] [Related]
50. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
Sampaio C; Bronzova J; Hauser RA; Lang AE; Rascol O; van de Witte SV; Theeuwes AA;
Mov Disord; 2011 Jul; 26(8):1464-76. PubMed ID: 21542016
[TBL] [Abstract][Full Text] [Related]
51. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
[TBL] [Abstract][Full Text] [Related]
52. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
Hauser RA; Stocchi F; Rascol O; Huyck SB; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt D
JAMA Neurol; 2015 Dec; 72(12):1491-500. PubMed ID: 26523919
[TBL] [Abstract][Full Text] [Related]
53. Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Giladi N; Tal J; Azulay T; Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe WH; Stocchi F; Tolosa E
Mov Disord; 2009 Apr; 24(5):655-61. PubMed ID: 19127595
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
[TBL] [Abstract][Full Text] [Related]
55. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
[TBL] [Abstract][Full Text] [Related]
56. Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Silver DE; Buck PO
Int J Neurosci; 2011 Sep; 121(9):485-9. PubMed ID: 21671840
[TBL] [Abstract][Full Text] [Related]
57. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
Stocchi F; Rascol O; Hauser RA; Huyck S; Tzontcheva A; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt DJ;
Neurology; 2017 Jun; 88(23):2198-2206. PubMed ID: 28490648
[TBL] [Abstract][Full Text] [Related]
58. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
[TBL] [Abstract][Full Text] [Related]
59. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
Jankovic J; Berkovich E; Eyal E; Tolosa E
Parkinsonism Relat Disord; 2014 Jun; 20(6):640-3. PubMed ID: 24637126
[TBL] [Abstract][Full Text] [Related]
60. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
Parkinson Study Group
Mov Disord; 2013 Nov; 28(13):1823-31. PubMed ID: 24123224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
